2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-179296
    SDH-IN-41 98%
    SDH-IN-41 (Compound 3d-1) is an antifungal agent, SDH inhibitor, with an IC50 value of 4.14 mg/L against SsSDH. SDH-IN-41 shows antifungal activity against S. sclerotiorum with an EC50 value of 1.86 mg/L.
    SDH-IN-41
  • HY-179301
    GuaB-IN-2 3096055-86-3
    GuaB-IN-2 (Compound 54) is a GuaB inhibitor, with an IC50 of 0.2 nM for M. tuberculosis GuaB. GuaB-IN-2 can be used in the research of bacterial infections and tuberculosis.
    GuaB-IN-2
  • HY-179376
    Anti-virulence factor-IN-3
    Anti-virulence factor-IN-3 (Compound 21) is a covalent β-aminosulfinyl type anthrax edema factor (EF) inhibitor, with a Ki value of 0.44 μM. Anti-virulence factor-IN-3 generates an active ethylene sulfinyl intermediate, which forms an irreversible covalent bond with the Lys residue at the active center of EF, permanently inhibiting the adenylate cyclase activity of EF. Anti-virulence factor-IN-3 effectively inhibits the cAMP production induced by EF, with an EC50 value of 0.15 μM. Anti-virulence factor-IN-3 can be used for research on anthrax Infection.
    Anti-virulence factor-IN-3
  • HY-179383
    DprE1-IN-14
    DprE1-IN-14 (Compound 77) is a DprE1 inhibitor, with an IC50 value of 2.5 nM for M. tb. DprE1-IN-14 exhibits anti-tuberculosis activity, with an MIC₉₀ of 0.3 μM for the M. tb mc26230 strain. DprE1-IN-14 mainly shows bacteriostatic activity, demonstrating a time-dependent bactericidal effect at 10-fold MIC concentrations. DprE1-IN-14 can be used in anti-tuberculosis research.
    DprE1-IN-14
  • HY-179396
    T-1228 1884551-35-2
    T-1228 is a highly selective LpxC inhibitor. T-1228 can effectively block the synthesis of LPS (HY-D1056), causing defects in the bacterial outer membrane structure, increasing membrane permeability, and ultimately leading to bacterial cell death. T-1228 can be used for the study of Gram-negative bacterial infections.
    T-1228
  • HY-179405
    Antibacterial agent 301
    Antibacterial agent 301 (compound 14c) is a pyridine-amide pleuromutilin derivative with broad-spectrum antibacterial and pronounced antimycoplasmal activity. Antibacterial agent 301 inhibits peptidyl transferase center (PTC), breaks down biofilms, and disrupts cell membranes in multidrug-resistant (MDR) bacteria. Antibacterial agent 301 exhibits activity in a systemic methicillin-resistant Staphylococcus aureus (MRSA) infection mouse model. Antibacterial agent 301 can be used for MDR bacterial infection research.
    Antibacterial agent 301
  • HY-179411
    Antifungal agent 139 25847-29-4
    Antifungal agent 139 (Compound li) is an antifungal agent that exhibits antifungal activity against Colletotrichum gloeosporioides by inhibiting CgSfu1 and CgRidA. Antifungal agent 139 completely inhibits mycelial growth, spore germination, and appressorium formation, with an EC50 of 18 μg/mL. Antifungal agent 139 can completely block the pathogen's infection of host plants (such as linden trees, cypress trees). Antifungal agent 139 can be used for research on anthrax.
    Antifungal agent 139
  • HY-179415
    DHFR-IN-24 1088704-78-2 98%
    DHFR-IN-24, a benzothiazole derivative, is a dihydrofolate reductase (DHFR) inhibitor. DHFR-IN-24 has intrinsic antibacterial activity against both Gram-positive and Gram-negative strains. DHFR-IN-24 synergistically combines DHFR inhibition with photodynamic therapy (PDT) for enhanced antibacterial activity against multidrug-resistant pathogens.
    DHFR-IN-24
  • HY-179437
    anti-HIV agent 1 98%
    anti-HIV agent 1 (compound 10i) is a potent antiviral agent with anti-HIV activity (IC50 = 10.6 nM). anti-HIV agent 1 exhibits moderate to no inhibitory activity against RT mutant strains, but maintains their activity against wild-type viruses. anti-HIV agent 1 strongly shows dual inhibition of the viral attachment and reverse transcriptase phases of the viral life cycle. anti-HIV agent 1 can be used for HIV infection research.
    anti-HIV agent 1
  • HY-179449
    CCHFV-IN-1 98%
    CCHFV-IN-1 (compound Z10) is a potent and selective Crimean-Congo hemorrhagic fever virus (CCHFV) inhibitor. CCHFV-IN-1 exhibits potent antiviral activity (EC50 = 0.60 μM) and high selectivity against CCHFV. CCHFV-IN-1 can be used for CCHFV infection research.
    CCHFV-IN-1
  • HY-179483
    CYP51-IN-31
    CYP51-IN-31 (compound T24) is a selective CYP51 inhibitor with potent and broad-spectrum antifungal activity, including efficacy against drug-resistant fungal strains. CYP51-IN-31 exhibits fungicidal activity against Candida parapsilosis, anti-biofilm activity, and the ability to inhibit fungal morphological transitions. CYP51-IN-31 can be used for infection research.
    CYP51-IN-31
  • HY-179493
    DHFR-IN-25 3002069-20-4
    DHFR-IN-25 (Compound N2) is a type of inhibitor of dihydrofolate reductase (DHFR). DHFR-IN-25 is a broad-spectrum and highly effective antibacterial agent, particularly showing significant effects on Candida albicans and Staphylococcus aureus. DHFR-IN-25 can be used for the study of local anti-infection.
    DHFR-IN-25
  • HY-179518
    Antifungal agent 140
    Antifungal agent 140 (compound 5p) is a potent antifungal agent with broad-spectrum antifungal activity. Antifungal agent 140 exerts a dual mechanism by targeting the Ras/cAMP/PKA pathway to inhibit hyphal formation and the ergosterol biosynthesis pathway. Antifungal agent 140 enhances survival, reduces fungal load in the kidneys, and strengthens host immune responses in a murine model of systemic candidiasis. Antifungal agent 140 can be used for research of resistant fungal infections.
    Antifungal agent 140
  • HY-179569
    Antiviral agent 73 98%
    Antiviral agent 73 (compound D13) is a potent intercellular movement inhibitor with antiviral activity. Antiviral agent 73 shows inactivation activity against potato virus Y (PVY) with an EC50 of 79.5 μg/mL. Antiviral agent 73 effectively inhibits virus infection by forming stable hydrogen bonds with Pro154 of PVY coat protein. Antiviral agent 73 can interfere with the process of Pro154-mediated viral intercellular trafficking in plasmodesmata. Antiviral agent 73 can be used for plant virus prevention and control.
    Antiviral agent 73
  • HY-179584
    Antileishmanial agent-38
    Antileishmanial agent-38 (compound 197) is a host-directed small molecule antileishmanial agent exhibiting potent broad-spectrum activity against Leishmania spp. Antileishmanial agent-38 inhibits intracellular parasites primarily by targeting the host protein lysozyme, while also displaying direct activity against extracellular L. donovani promastigotes. Antileishmanial agent-38 can be used for leishmaniasis research.
    Antileishmanial agent-38
  • HY-179611
    LP-03
    LP-03 is an antibacterial agent with selective activity against Methicillin-resistant Staphylococcus aureus (MRSA). Its minimum inhibitory concentration (MIC) is 6.2 μM. LP-03 has an inhibitory effect on biofilm formation, but it is unable to effectively remove the formed biofilms. LP-03 can enhance membrane permeability, disrupt the membrane structure of MRSA cells, and does not cause significant membrane depolarization. LP-03 has no hemolytic toxicity and shows low mammalian cell toxicity. It can be used for research on MRSA infections.
    LP-03
  • HY-179612
    SARS-CoV-2 3CLpro-IN-34
    SARS-CoV-2 3CLpro-IN-34 (Compound 55) is a highly efficient non-covalent inhibitor of the SARS-CoV-2 3CLpro protease (b. SARS-CoV-2 3CLpro protease) with an IC50 of 1.9 μM. SARS-CoV-2 3CLpro-IN-34 can inhibit the 3CLpro protein of SARS-CoV-1, with its IC50 being 3.2 μM, and it shows high selectivity towards host cysteine proteases (such as cathepsins L/K and calpain). SARS-CoV-2 3CLpro-IN-34 exhibits antiviral activity in cells infected with SARS-CoV-2, with its EC50 being 25 μM, and it is not affected by P-gp inhibitors and shows no significant cytotoxicity. SARS-CoV-2 3CLpro-IN-34 can be used for research on SARS-CoV-2 infection.
    SARS-CoV-2 3CLpro-IN-34
  • HY-179632
    Antibacterial agent 311 2349248-62-8
    Antibacterial agent 311 (Compound 4f) is an antibacterial agent. Antibacterial agent 311 exhibits antibacterial activities against P. aeruginosa, S. aureus, E. coli, K. pneumonia, E. CTXM1, E. NDM1 with MICs of 0.8, 1, 1, 1, 0.7, 0.7 mg/mL.
    Antibacterial agent 311
  • HY-179670
    Antibacterial agent 304 2771231-72-0
    Antibacterial agent 304 (Compound 3a) is an antibacterial agent with a minimum inhibitory concentration (MIC) of 8 μg/mL against S. aureus and P. aeruginosa. This antibacterial agent has a bactericidal effect and can disrupt the integrity of the cell wall. Antibacterial agent 304 has the potential to be a sustainable organic photocatalyst.
    Antibacterial agent 304
  • HY-179704
    Antifungal agent 141
    Antifungal agent 141, a Phenoxazine (HY-34463) derivative, is an antifungal agent. Antifungal agent shows potent antifungal activity in Cryptococcus neoformans and Candida albicans with MIC values of 2 and 4 µg/mL. Antifungal agent 141 can be used for the research of cryptococcal meningitis.
    Antifungal agent 141
Cat. No. Product Name / Synonyms Application Reactivity